Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 3 Trial
Recent news which mentions Phase 3 Trial
< Previous
1
2
3
4
5
6
7
8
Next >
Gilead Churns Out Additional Trodelvy Data
September 16, 2021
Tickers
GILD
Tags
GILD
Biotech
breast cancer
From
Benzinga
BeyondSpring Presents New Plinabulin Data At ESMO Congress
September 16, 2021
Tickers
BYSI
Tags
Briefs
Neutropenia
BYSI
From
Benzinga
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
September 16, 2021
Tickers
BMY
EXEL
PFE
Tags
Benzinga
Biotech
renal cell carcinoma
From
Benzinga
EXCLUSIVE: Ampio's Ampion Shows Benefit In Late-Stage Knee Osteoarthritis Study
September 15, 2021
Tickers
AMPE
Tags
AMPE
Briefs
Phase 3 Trial
From
Benzinga
What's Happening With RedHill Biopharma's Stock On Tuesday?
September 14, 2021
Tickers
RDHL
Tags
Phase 3 Trial
General
News
From
Benzinga
Mimedx Stock Plunges After Disappointing Data From Musculoskeletal Trials
September 13, 2021
Tickers
MDXG
Tags
Short Ideas
Biotech
FDA
From
Benzinga
Valneva Shares Plunge As UK Terminates COVID-19 Vaccine Contract: What You Need Know
September 13, 2021
Tickers
DVAX
VALN
Tags
Phase 3 Trial
VALN
News
From
Benzinga
Apellis Unveils Mixed Results For Eye Disorder Drug, But Still Hopes To Pass FDA Finish Line
September 10, 2021
Tickers
APLS
Tags
Briefs
Trading Ideas
Phase 3 Trial
From
Benzinga
AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings
September 09, 2021
Tickers
AZN
AZNCF
Tags
Health Care
Market News
AZNCF
From
Benzinga
Sanofi's BTK Inhibitor Disappoints In Phase 3 Autoimmune Disease Trial
September 09, 2021
Tickers
SNY
Tags
SNY
General
News
From
Benzinga
AstraZeneca's Two Asthma Trials Meet Primary Endpoints
September 09, 2021
Tickers
AZN
RPRX
Tags
Market News
RPRX
Health Care
From
Benzinga
MacroGenics' Cancer Drug Margenza Flops On Overall Survival Analysis
September 08, 2021
Tickers
MGNX
RHHBF
RHHBY
RHHVF
Tags
Phase 3 Trial
General
News
From
Benzinga
See Why Travere Therapeutics Stock Moving Higher On Tuesday
September 07, 2021
Tickers
TVTX
Tags
Biotech
FDA
Benzinga
From
Benzinga
Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab
September 07, 2021
Tickers
AMGN
AZN
AZNCF
Tags
General
News
Phase 3 Trial
From
Benzinga
RedHill Unveils New Movantik Data For Opioid-Induced Constipation
September 07, 2021
Tickers
RDHL
Tags
Briefs
Benzinga
RDHL
From
Benzinga
See Why RenovoRx Stock Is Shooting Higher On Tuesday
September 07, 2021
Tickers
RNXT
Tags
Movers
Health Care
RNXT
From
Benzinga
Pfizer Starts Late-Stage Trial For RSV Vaccine Candidate In Older Patients
September 02, 2021
Tickers
PFE
Tags
Biotech
REspiratory syncytial virus
Benzinga
From
Benzinga
Takeda's Breakthrough Blood Cancer Drug Flunks In Phase 3 Study
September 02, 2021
Tickers
TAK
TKPHF
Tags
TAK
Briefs
Trading Ideas
From
Benzinga
Merck To Test Oral Antiviral Candidate For Post-Exposure Prophylaxis Of COVID-19 Infection
September 01, 2021
Tickers
MRK
Tags
Benzinga
Biotech
MRK
From
Benzinga
Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review
September 01, 2021
Tickers
TEVA
Tags
News
General
TEVA
From
Benzinga
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
August 31, 2021
Tickers
AZN
CVAC
GSK
SNY
Tags
Biotech
GSK
Benzinga
From
Benzinga
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
August 30, 2021
Tickers
PFE
REGN
SNY
Tags
Briefs
Benzinga
REGN
From
Benzinga
Eli Lilly, Boehringer Share Jardiance Data In Heart Failure Field
August 27, 2021
Tickers
LLY
Tags
Biotech
LLY
Benzinga
From
Benzinga
Amgen's Repatha Improves Plaque Stability In Heart Patients
August 27, 2021
Tickers
AMGN
Tags
Briefs
Benzinga
Biotech
From
Benzinga
AstraZeneca's Drug Shows Promise In Copper Build-Up Genetic Disease
August 26, 2021
Tickers
AZN
AZNCF
Tags
AZN
Genetic Disorder
Briefs
From
Benzinga
Edesa Biotech Provides Update For COVID-19 Antibody Trial
August 26, 2021
Tickers
EDSA
Tags
News
General
Phase 3 Trial
From
Benzinga
Inovio To Start Global Late-Stage COVID-19 Vaccine Trial
August 26, 2021
Tickers
INO
SVA
Tags
Benzinga
FDA
Biotech
From
Benzinga
Amneal's Parkinson's Candidate Shows Efficacy In Pivotal Trial
August 26, 2021
Tickers
AMRX
Tags
News
General
Parkinson’s Disease
From
Benzinga
Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment
August 25, 2021
Tickers
EBS
Tags
Briefs
National Institutes of Health
News
From
Benzinga
Cassava Sciences Receives FDA's Special Protocol Assessment For Alzheimer's Trials
August 24, 2021
Tickers
SAVA
Tags
Biotech
FDA
Benzinga
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.